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http://dx
894Objective: Restoring dual blood supply to transplanted lungs by bronchial artery revascularization (BAR)
remains controversial. We compared outcomes after lung transplantation performed with and without BAR.
Methods: From December 2007 to July 2010, 283 patients underwent transplantation; 187 were 18 years or
older, without previous or concomitant cardiac surgery. Of these patients, 27 underwent BAR in a pilot study
to test success, safety, effectiveness, and teachability. A propensity score was generated to match BAR patients
and 54 routine non-BAR patients. Follow-up was 1.3  0.68 years.
Results:BARwas angiographically successful in 26 (96%) of 27 patients. BAR and non-BAR patients had sim-
ilar skin-to-skin time (P ¼ .07) and postoperative hospital stays (P ¼ .2), but more reoperations for bleeding
(P ¼ .002). Tracheostomy was performed in 9 (33%) of 27 BAR and 10 (19%) of 54 non-BAR patients
(P ¼ .2, log-rank). One BAR (3.7%) and 4 non-BAR (7.4%) patients required extracorporeal membrane oxy-
genation (P ¼ .7). Airway ischemia was observed in 1 BAR (3.7%) versus 12 non-BAR (22%) patients
(P ¼ .03); anastomotic intervention was required in no BAR versus 8 non-BAR (15%) patients
(P ¼ .04). Hospital mortality was 1 of 27 versus 2 of 54 (P ¼ .9). BAR patients had lower early biopsy tissue
rejection grades (P ¼ .008) and fewer pulmonary (P< .04) and bloodstream (P< .02) infections. Forced
1-second expiratory volume was similar (P>.2); 3 BAR versus 9 non-BAR patients developed bronchiolitis
obliterans syndrome (BOS) (P ¼ .14, log-rank). During follow-up, 4 BAR and 8 non-BAR patients died
(P ¼ .6, log-rank).
Conclusions: BAR is safe, with comparable early outcomes. Benefits of BAR include reduced airway ischemia
and complications, lower biopsy tissue grades, fewer infections, and delay of BOS. A multicenter study is
needed to establish these benefits. (J Thorac Cardiovasc Surg 2013;146:894-900)Video clip is available online.e Department of Thoracic and Cardiovascular Surgery,a Heart and Vascular
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Outcomes after lung transplantation remain worse than those
after heart, liver, or kidney transplantation. The 2 main causes
of death are infections and obliterative bronchiolitis (OB),
small airway fibrosis resulting in progressive loss of lung func-
tion.1 After establishing OB as a manifestation of chronic re-
jection, recent research has focused attention on airway
ischemia as a probable important cause.2 Normal lungs have
a dual blood supply, but routine lung transplantation does not
include restoring bronchial artery blood supply. The technique
of bronchial artery revascularization (BAR) is well described
and has been successful in small series.3-5 The largest series
of en bloc double-lung transplants with BAR, from Copenha-
gen, Denmark, demonstrated excellent success and long-term
survival, superior to the more recent series of sequential bilat-
eral non-BAR lung transplants from the same institution.6,7
These favorable long-term outcomes reported from Co-
penhagen inspired the Cleveland Clinic (Cleveland, Ohio)
lung transplant group to revisit BAR.A pilot study to confirmery c October 2013
Abbreviations and Acronyms
BAR ¼ bronchial artery revascularization
BOS ¼ bronchiolitis obliterans syndrome
CL ¼ confidence limit
CPB ¼ cardiopulmonary bypass
FEV1 ¼ forced 1-second expiratory volume
FEV1% ¼% of predicted FEV1
IRB ¼ Institutional Review Board
OB ¼ obliterative bronchiolitis
PGD ¼ primary graft dysfunction
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and to prove teachability, was initiated in December 2007.
Halfway into the study, we have compared outcomes after
BAR with those after routine non-BAR lung transplantation.
METHODS
Patients
From December 1, 2007, to July 1, 2010, 283 lung transplantations (3
liver/lung, 6 heart/lung, and 274 lung only) were performed at Cleveland
Clinic; 187 were lung transplant only in patients 18 years or older without
previous or concomitant cardiac surgery. Of these, 20 (74%) double-lung
and 7 (26%) single-lung transplants were performed with BAR and 160
without BAR (Table E1).
BAR operations were performed as an Institutional Review Board
(IRB)–approved pilot study, with separate patient consent required for
the angiogram to verify BAR patency, and Data and Safety Monitoring
Board adjudication of adverse events. The IRB stipulated that one surgeon
(G.B.P.) perform the first 25 BAR lung transplants to demonstrate results
equivalent to his Copenhagen experience,5,6 then teach other surgeons to
perform the procedure on the subsequent 25.
During the pilot, all lung transplant recipients are being approached,
and most have consented for BAR. However, transplants performed
when G.B.P. is unavailable are not permitted to be done with BAR.
For single-lung transplants, bronchial anatomy allows BAR for both
lungs in less than 50% of cases. Dividing the donor block requires ex-
perience identifying bronchial arteries, and we are not confident at this
stage to do this at the donor hospital. This limits BAR for single-lung
transplantation to blocks brought back undivided. In addition, occasion-
ally, anatomy and arterial sclerosis in the donor aorta preclude ability to
perform BAR.
Study Design
Because the IRB did not permit a randomized trial to be performed, but
only a pilot study to demonstrate proficiency and safety, we performed
a propensity-matched comparison of outcomes with contemporaneous
routine non-BAR lung transplantation.8
Surgical Techniques
Donor lungs for BAR are procured en bloc with the esophagus and
descending aorta to secure inclusion of the retroesophageal right intercos-
tobronchial artery. Lung transplants with BAR are performed according to
techniques previously described.9-15 One internal thoracic artery is
harvested. Double-lung transplantation is performed en bloc via sternot-
omy using cardiopulmonary bypass (CPB) with tracheal anastomosis.
For en bloc transplants, the BAR anastomoses are performed first, followed
by the trachea, pulmonary trunk, and left atrium anastomoses. The internal
thoracic artery is anastomosed to 1 or more bronchial artery ostia in theThe Journal of Thoracic and Cadonor descending aorta. For single-lung transplantation, which is not per-
formed on CPB, the bronchial anastomosis is performed at the secondary
carina, as in non-BAR transplants. The BAR anastomosis is performed
last, after giving 10,000 IU heparin and after pulmonary artery reperfusion.
In this pilot study, transplants without BAR are performed by estab-
lished techniques as sequential bilateral or single-lung transplants. The
donor bronchus is divided immediately proximal to the secondary carina,
and anastomosis is performed with a nonresorbable monofilament suture,
running or interrupted, without intent to telescope one end into the other.
CPB is used as needed or according to surgeon preference.End Points
Procedure success. Visualization of any bronchial arteries after
selective contrast injection into the internal thoracic artery conduit was
considered successful BAR. Although noninvasive imaging has success-
fully identified bronchial artery patency in most instances, it remains im-
perfect.16 Thus, in this pilot study, direct angiography is required by the
Institutional Review Board.
Safety. Variables related to safety of BAR included CPB time, skin-to-
skin operative time, reoperation for bleeding, intensive care unit and post-
operative lengths of stay, requirement for tracheostomy, posttransplant
extracorporeal membrane oxygenation support, and hospital mortality.
Clinical effectiveness. Clinical effectiveness was assessed by evi-
dence of airway ischemia and airway interventions, lung biopsy tissues
for rejection grade, primary graft dysfunction (PGD) grade, serious
infections, forced 1-second expiratory volume (FEV1) normalized to %
of predicted (FEV1%), bronchiolitis obliterans syndrome (BOS), and
intermediate-term survival.
Evidence of airway issues, possibly related to ischemia, was abstracted
from each bronchoscopy laboratory report and review of images to confirm
positive findings. Findings of avascularmucosa, mucosal sloughing, necrosis,
ulcer, anastomotic dehiscence, or late airway stenosis were considered poten-
tially related toairway ischemia.Airway interventionwas recorded separately.
Posttransplant routine lung biopsy specimens were graded according to
the Lung Rejection Study Group classification system.17 For this study, we
focused on perivascular rejection grades A0 through A4. The number of
biopsy specimens available across time is depicted in Figure E1, A. Based
on this distribution, we reliably estimated the prevalence of each grade up
to 1.25 years posttransplant.
PGD was graded according to The International Society for Heart and
Lung Transplantation guidelines.18 All patients had PGD data available
at 0, 24, 48, and 72 hours after transplant.
All infections occurring within 1 year in all lung transplant patients
were reviewed, adjudicated, and categorized in a completely blinded man-
ner by an infectious disease physician (R.K.A.). The same infection
prophylaxis was used in BAR and non-BAR patients.
Results of all spirometry assessments performed in the Cleveland Clinic’s
certified pulmonary function laboratory, which conforms to the standards of
theAmerican Thoracic Society, were retrieved from the Pulmonary Function
Test database. These included National Health and Nutrition Examination
Survey–normalized postoperative FEV1%,19,20 which was the primary
variable analyzed. The number of pulmonary function tests available for
analysis across time is shown in Figure E1, B. BOS was defined and graded
by reduction in FEV1%.21 Data related to BOS were reviewed, adjudicated,
and gradedby anexperiencedpulmonologist (M.M.B.) and include pre-BOS.
Survival was ascertained by annual anniversary follow-up as of March
31, 2011. No patient was lost to follow-up. The mean follow-up time
among survivors was 1.3  0.68 years (median, 1.06 years); 10% were
followed up for more than 2.1 years.
Data
Datawere retrieved from the Electronic Data Interface for Transplant da-
tabase, the Cardiovascular Information Registry, and the Pulmonaryrdiovascular Surgery c Volume 146, Number 4 895
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from medical record review. Use of these data for research was approved
by the Cleveland Clinic Institutional Review Board, with patient consent
waived.
Data Analysis
Propensity score matching. Multivariable logistic regression was
performed to identify preoperative factors associated with 27 BAR patients
versus 160 non-BAR patients, considering variables listed in Appendix E1.
Initially, a parsimonious model was developed using bagging with auto-
mated analysis of 500 resampled data sets for variable selection at P 
.05.22,23 BAR patients had a longer wait list time (P ¼ .0005), but were
less likely to have chronic obstructive pulmonary disease, emphysema,
or a-1 antitrypsin deficiency (P ¼ .003).
We augmented this model with additional prespecified patient factors
noted in Appendix E1, regardless of their statistical significance
(C-statistic ¼ .81). By using the resulting propensity model, we calcu-
lated a propensity score for each patient, which was used in nearest-
neighbor matching with replacement (bootstrap strategy) of 1 BAR
patient to 2 non-BAR patients. Patients were well matched, as demon-
strated by standardized differences before and after matching (Table 1
and Figure E2).
Safety. Categorical variables are summarized by frequencies and
percentages, with comparisons made using the c2 or Fisher exact test. Con-
tinuous variables are summarized as mean and SD, or equivalent median
and 15th and 85th percentiles for skewed variables. Continuous variables
were compared using the Wilcoxon rank-sum test. For consistency, 68%
confidence limits (CLs) or bands are used, equivalent to 1 SE.
Tracheostomy was treated as a time-related event assessed nonparamet-
rically by the Kaplan-Meier method. BAR and non-BAR estimates were
compared using the log-rank test. These methods were used for all time-
related events.
Clinical effectiveness. Airway ischemia at bronchoscopy and
airway interventions were treated as time-related events.
Lung biopsy specimen rejection data were analyzed as a longitudinal
repeated-measures ordinal variable. Time from transplant to biopsy ranged
from 0 to 2.9 years (median, 3.8months). Because of sparse data, grades A2
and A3were combined into 1 group (grade A2þ). Consequently, an ordinal
scale of 3 grades was analyzed: 0, A1, and A2þ. No patient in the study
cohort had biopsy tissue grade A4. Amultiphase nonlinear cumulative logit
mixed model (SAS PROC NLMIXED; SAS Institute, Inc, Cary, NC) was
used to resolve several time phases (temporal decomposition), estimate the
shaping parameters of each phase, and determine the temporal trend of the
patient-specific prevalence of each biopsy tissue grade over time,24 assum-
ing a multinomial distribution. To determine the effect of BAR, we forced
the group variable into each phase of the model.
Pulmonary, bloodstream, and overall infections were analyzed as possi-
bly repeating events using the method of Nelson,25 with comparison by the
log-rank test.
PGD scores were analyzed in the same manner as described for lung
biopsy specimens, but at 4 points: immediately after transplant and after
24, 48, and 72 hours.
Postoperative lung function was evaluated using FEV1 (% of pre-
dicted). At least 1 spirometry measurement was made after transplant for
25 (93%) BAR patients and 48 (89%) non-BAR patients. Overall, 727
spirometry assessments were analyzed (243 in BAR and 484 in non-
BAR patients). The median collection time of FEV1 was 0.44 years (range,
13 days to 2.9 years) (Figure E1, B). Based on the distribution of spirometry
examinations, we reliably estimated average FEV1 (% of predicted) up to
1.5 years posttransplant. The continuous repeated measurements of FEV1
were analyzed longitudinally across time, similar to the biopsy data.
Because of few occurrences of BOS, all grades, including pre-BOS,
were considered together as a binary outcome. It was analyzed as a longi-
tudinal cross-sectional outcome, an interval-censored outcome, and a single896 The Journal of Thoracic and Cardiovascular Surgtime-related event. All analyses yielded consistent estimates; thus, simple
Kaplan-Meier estimates are depicted, with several different tests of differ-
ences between BAR and non-BAR patients made. Survival was estimated
nonparametrically by the Kaplan-Meier method.RESULTS
Procedure Success
Angiography demonstrated patent BAR in 24 of the 25
patients in whom the internal thoracic artery was injected
(Video 1). One patient (with normal airway healing) refused
the imaging study, and another died 6 weeks after transplan-
tation and before imaging; autopsy demonstrated patent
BAR and a normally healing airway.
Safety
BAR and non-BAR patients had similar CPB (relevant
for double-lung transplants: 164  32 [n ¼ 20] vs 178 
78 [n ¼ 37] minutes; P ¼ .3) and skin-to-skin (350  71
vs 318  86 minutes; P ¼ .07) times, and postoperative in-
tensive care unit (15th/median/85th percentiles, 3/7/23 vs 2/
5/21 days; P¼ .16) and postoperative lengths of stay (15th/
median/85th percentiles, 10/19/57 vs 8/15/31 days; P¼ .2).
BAR patients required more reoperations for bleeding (10
[37%] vs 5 [9.3%]; P ¼ .002), but with no difference in
need for transfusion (P ¼ .6). After transplant, 9 BAR and
10 non-BAR patients required tracheostomy. These were
performed between days 8 and 40 in the BAR group and
between days 3 and 24 in the non-BAR group (P ¼ .2,
log-rank). Extracorporeal membrane oxygenation was
used in 1 BAR patient on posttransplant day 1 and in 4
non-BAR patients, 1 at transplant and 1 on days 1, 9, and
17 (P ¼ .7, log-rank). The chest needed to be left open,
then closed postoperatively, in a similar proportion of
patients (2 BAR patients and 4 non-BAR patients, 7.4%
each). One BAR patient (3.7%) required decortication post-
operatively. No sternal wound infections occurred in either
group.
Clinical Effectiveness
Airway ischemia and interventions. One BAR patient ex-
perienced airway ischemia issues (3.7%; CL, 0.6%-12%)
compared with 12 non-BAR patients (22%; CL, 16%-
29%) (P ¼ .03, Fisher exact test; Videos 2 and 3). The
airway ischemia in the BAR patient was evident on day 14.
For non-BAR patients, it occurred between day 13 and 7
months posttransplant (Figure 1). No BAR patient had an
anastomotic intervention (CL, 0%-6.6%), whereas 8 non-
BAR patients did (15%; CL, 9.9%-21%) (P ¼ .04, Fisher
exact test). These interventions occurred between day 36
and 9.5 months posttransplant (Figure 2). Three patients re-
quired balloon bronchial dilatation only, and 5 required mul-
tiple and complex interventions, including airway stenting.
Primary graft dysfunction. Although BAR procedure
patients seemed to have higher PGD scores than matchedery c October 2013
TABLE 1. Characteristics of BAR and non-BAR 1:2 matched patients
Characteristic
BAR (n ¼ 27) Non-BAR (n ¼ 52)
P
valuen*
No. (%) or
mean ± SD
15/50/85
Percentiles n*
No. (%) or
mean ± SD
15/50/85
Percentiles
Recipient
Demographics
Age, y 27 50  13 35/52/64 54 52  14 37/58/66 .4
Female sex 27 11 (41) 54 22 (41) >.9
Primary diagnosis
COPD, emphysema, or a-1 antitrypsin disease 27 3 (11) 54 6 (11) >.9
Cystic fibrosis or bronchiectasis 27 4 (15) 54 9 (17) .8
Idiopathic pulmonary fibrosis 27 12 (44) 54 27 (50) .6
Pulmonary hypertension 27 2 (7.4) 54 3 (5.6) .7
Lymphangiomyomatosis 27 0 (0) 54 2 (3.7) >.9
Non–transplant-related bronchiolitis obliterans syndrome 27 1 (3.7) 54 2 (3.7) >.9
Sarcoidosis 27 1 (3.7) 54 3 (5.6) .7
Other diagnosisy 27 4 (15) 54 2 (3.7) .08
Comorbidities
Smoking 27 13 (48) 54 31 (57) .4
Diabetes 27 4 (15) 54 7 (13) .8
Hypertension 27 4 (15) 54 7 (13) .8
GERD 27 6 (22) 54 13 (24) .8
Serum creatinine, mg/dL 26 0.8  0.19 0.6/0.78/1 50 0.76  0.23 0.5/0.77/1 .4
Waiting time and allocation
Time on waiting list, d 27 197  245 26/99/475 54 208  256 22/91/475 .9
Lung allocation score 27 46  16 33/43/59 54 44  14 34/39/51 .6
Pulmonary artery pressures, mmHg
Systolic 14 41  20 24/38/69 25 44  15 32/42/55 .4
Diastolic 14 18  10 6.8/16/32 25 18  10 9.7/17/24 .8
Mean 14 26  13 13/23/45 25 27  11 16/25/34 .7
Double-lung transplant 27 20 (74) 54 37 (69) .6
Donor
Demographics
Age, y 27 35  14 19/36/50 54 39  15 19/43/55 .3
Cause of death
Anoxia 27 4 (15) 54 13 (24) .3
Cerebrovascular 27 9 (33) 54 16 (30) .7
Head trauma 27 11 (41) 54 20 (37) .8
Other 27 3 (11) 54 4 (7.4) .6
Recipient-donor matching
Sex mismatch 27 4 (15) 54 21 (39) .03
BAR, Bronchial artery revascularization; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease. *Patients with data available. yFor BAR: 2
eosinophilic granulomas, 1 mixed connective tissue disease, and 1 Sjogren syndrome. For non-BAR: 1 mixed connective tissue disease and 1 bronchoalveolar carcinoma.
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nificant (P  .4, Figure 3).
Rejection. During the first 3 months after lung transplant,
freedom from rejection (prevalence of grade A0) was higher
in BAR than non-BAR patients (average, 77% vs 57%;
P¼ .008) (Figure 4 and Figure E3 for other grades). Thereaf-
ter, distribution of biopsy tissue grades was similar (P  .7).
Infection. Within the first year after transplantation, pul-
monary infection occurred in 7 BAR patients and 42
non-BAR patients (Figure 5), such that by 1 year after
BAR, the estimated event number per 100 patients was 30,
and after non-BAR, it was 58 (P<.04). Bloodstream infec-
tions occurred in 2 BAR and 19 non-BAR patientsThe Journal of Thoracic and Ca(Figure E4 and Table E2). There were no sternal wound
infections.
Lung function. In both BAR and non-BAR groups, aver-
age FEV1% plateaued at 6 months posttransplant. Values
were similar at that time (68% for BAR and 72% for
non-BAR patients; P> .2) (Figure 6). By last follow-up,
3 BAR and 9 non-BAR patients had developed pre-BOS or
BOS. Among BAR patients, BOS grade was pre-BOS in
2 and grade 3 in 1; among non-BAR patients, 5 had
pre-BOS and 1 had grade 1, 2 had grade 2, and 1 had grade
3. Freedom from BOS at 24 months after transplant was
92% among BAR patients and 58% among non-BAR
patients (Figure 7). Because of distribution of events afterrdiovascular Surgery c Volume 146, Number 4 897
FIGURE 3. Stacked bar graph of primary graft dysfunction grades 0 to 3
at 0, 24, 48, and 72 hours after lung transplant for bronchial artery revascu-
larization (BAR) and propensity-matched non-BAR patients.
FIGURE 1. Freedom from airway ischemia stratified by bronchial artery
revascularization (BAR) and non-BAR (propensity-matched patients).
Symbols are nonparametric estimates, and vertical bars are 68% confi-
dence limits equivalent to 1 SE. Numbers in parentheses are patients re-
maining at risk. The dashed line for the BAR group indicates absence of
events beyond the first one.
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value favoring BAR ranged from .07 (Wilcoxon test) to
.14 (log-rank test).
Survival. To date, 4 deaths have occurred among BAR pa-
tients, at 1.5 months and 1.7, 1.8, and 2.2 years; 8 deaths
have occurred among non-BAR patients between day 1
and 2.1 years posttransplant. Nonparametric survival esti-
mates at 1, 3, and 6 months and 1 and 2 years were
100%, 96%, 96%, 96%, and 83% for BAR patients and
96%, 96%, 93%, 90%, and 80% for non-BAR patients, re-
spectively (P¼ .6, log-rank) (Figure 8). Causes of death are
listed in Table 2.FIGURE 2. Freedom from posttransplant anastomotic intervention for
propensity-matched bronchial artery revascularization (BAR) and non-
BAR patients. Therewere no such interventions in BAR patients. Depiction
is as in Figure 1.
898 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
New evidence shows that ischemia is important in the
pathogenesis of airway fibrosis, a key element responsible
for OB, causing progressive loss of function (BOS) and
death in many patients after lung transplantation.2 Al-
though cutting back and anastomosing the donor bronchus
at the secondary carina may reduce anastomotic
complications and need for interventions, it does not alter
distal airway and lung tissue ischemia resulting from
ignoring bronchial artery circulation.26,27 Successful
BAR should consistently provide a normal nonischemic
airway (Videos 2 and 3).
The Copenhagen series showed high procedural success,
safety, and excellent long-term outcomes after BAR.7 In the
absence of other larger series, however, this single seriesFIGURE 4. Proportion of patients in vascular rejection grade 0 after lung
transplantation, according to whether bronchial artery revascularization
(BAR) was performed (propensity-matched patients). Symbols are actual
grouped data, without regard to repeated measurements, used as a crude
verification of the model.
ery c October 2013
FIGURE 5. Cumulative incidence of pulmonary infections during the first
year after transplantation among propensity-matched bronchial artery re-
vascularization (BAR) and non-BAR patients. Depiction is as in Figure 1,
except that the vertical axis is cumulative incidence, and number of patients
remaining at risk is greater because patients remain at risk of infections.
FIGURE 7. Freedom from bronchiolitis obliterans syndrome (BOS)
after lung transplant for bronchial artery revascularization (BAR) and
propensity-matched non-BAR patients. Depiction is as in Figure 1.
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that BAR was worthwhile, given the added complexity of
both harvesting and transplantation. The Cleveland Clinic
pilot study has so far confirmed feasibility with high proce-
dural success, as evidenced by angiographic patency of the
internal thoracic artery and perfusion of the airway, relative
safety, and clinical effectiveness. Because of small num-
bers, we did not attempt to associate outcomes with grade
of angiographic success of BAR.
The present study represents a first attempt to compare
outcomes after lung transplantation with and without
BAR in matched patients. BARwas associated with less air-
way ischemia, did not require airway interventions, and had
otherwise comparable safety, except for a higher risk of re-
operation for bleeding, which exceeded that observed in the
Copenhagen series. A new, possibly important, finding in
this comparison study was that BAR patients had less earlyFIGURE 6. Estimated mean forced 1-second expiratory volume (FEV1)
after lung transplant, stratified by bronchial artery revascularization
(BAR) and propensity-matched non-BAR patients. Format is as in Figure 4.
The Journal of Thoracic and Caevidence of rejection. This adds an immunologic mecha-
nism to the apparent airway ischemia and other factors con-
tributing to development of airway fibrosis, BOS, and OB.
Altered antigen presentation and immunologic response
may both be secondary to ischemia.
A second new finding was substantially fewer pulmonary
and bloodstream infections after transplantation with BAR.
We speculate that this finding may be related, in part, to
bronchial blood flow with a healthier airway. In addition,
in BAR patients, there was less opportunity for bacterial
colonization, which is likely increased in those requiring
interventions and stents and in those who have ischemic,
necrotic, dehisced, or stenotic segments of their airway. A
third finding is possibly somewhat delayed development
of BOS, in accordance with a Copenhagen finding,28 which
may relate to the combined effect of reduced bronchial
ischemia, lower-grade rejections, and fewer infections.FIGURE 8. Survival after lung transplant for bronchial artery revascular-
ization (BAR) and propensity-matched non-BAR patients. Depiction is as
in Figure 1.
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TABLE 2. Cause of death in matched patients after BAR and non-
BAR lung transplantation
Cause BAR (n ¼ 4) Non-BAR (n ¼ 8)
Cerebral 0 (0) 2 (25)
Infection 0 (0) 1 (12)
Malignancy 1 (25) 2 (25)
Organ failure 1 (25) 1 (12)
Brainstem herniation 1 (25) 0 (0)
Respiratory failure 1 (25) 1 (12)
Hemorrhage (nonstroke) 0 (0) 1 (12)
Data are given as number (percentage) of patients. BAR, Bronchial artery revascular-
ization.
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This is a single-center study performed as part of an on-
going pilot study of restarting a BAR program after the suc-
cess of the Copenhagen experience. It reflects specific
restrictions imposed by the IRB, including its nonrandom-
ized nature. To compensate for this, we have performed
a propensity-matched BAR versus non-BAR study.
Technical difficulty remains an obstacle to wider accep-
tance of BAR. This obstacle is related to the fact that
most lung transplant surgeons are general thoracic surgeons
not used to performing internal thoracic artery anastomoses
daily. BAR patients required more reoperations for bleeding
early in the series, often because of the BAR anastomosis.
Anastomosing the internal thoracic artery to the aortic ostia
of the bronchial arteries is different from coronary anasto-
mosis and requires practice. This highlights the importance
of the second half of our pilot study, which is to study teach-
ability of BAR.CONCLUSIONS
Although associated with an elevated risk of reoperation
for bleeding, BAR can be performed successfully and rela-
tively safely and is associated with reduced airway ische-
mia, less early rejection, and fewer pulmonary infections
compared with when bronchial artery circulation is ignored.
These benefits of BAR are likely to have a long-term effect
on late-developing BOS, a trend already observed in this
study. These findings are encouraging enough to support
a call for a multicenter trial to establish the benefits of BAR.References
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APPENDIX E1. Variables Considered in All Multivariable Analyses
Recipient
Demographics: Age (y)*, sex*, weight (kg), height (cm), body mass
index (kg$m2), body surface area (m2), weight-height ratio, race
Diagnosis: Chronic obstructive pulmonary disease, emphysema, or a-1
antitrypsin disease*; cystic fibrosis or bronchiectasis*; idiopathic
pulmonary fibrosis*; pulmonary hypertension; sarcoidosis
Comorbidities: Smoking*, diabetes*, gastroesophageal reflux disease*,
hypertension, serum creatinine (mg/dL), total bilirubin (mg/dL),
hematocrit (%), blood urea nitrogen (mg/dL), creatinine clearance,
glomerular filtration rate, total protein (mg/dL)
Waiting time and allocation: Days on waiting list*, lung allocation
score*
Systemic pressures (mmHg): Systolic*, diastolic*, mean
Blood type: A/A1/A2, AB, B, O
Surgical: Cardiopulmonary bypass time (min), double or single lung
transplant*, ischemic time (min)
Donor
Demographics: Age (y), sex, weight (kg), height (cm), body mass index
(kg$m2), body surface area (m2), weight-height ratio, race
Comorbidities: Smoker, serumcreatinine (mg/dL), total bilirubin (mg/dL),
blood urea nitrogen (mg/dL)
Blood type: A/A1/A2, AB, B, O
Cause of death: Anoxia, cerebrovascular, head trauma
Recipients þ Donor
Race mismatch, sex mismatch, weight ratio
*Variables in propensity model.
Pettersson et al Cardiothoracic TransplantationFIGURE E1. Number of test results available across time for bronchial
artery revascularization (BAR) and propensity-matched non-BAR patients.
A, Lung biopsy specimens. B, Pulmonary function test results.
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FIGURE E2. Quality and extent of propensity-based matching. A, Covariate balance description before (red triangles) and after (green squares) matching
between bronchial artery revascularization (BAR) and non-BAR groups. B,Mirrored histogram of distribution of propensity scores for BAR versus non-BAR
groups. Light and dark green areas represent matched patient pairs.
FIGUREE3. Proportion of patients in vascular rejection grades other than
0 after lung transplantation, according to whether bronchial artery revascu-
larization (BAR) was performed (propensity-matched patients). Symbols
are actual grouped data, without regard to repeated measurements, used
as a crude verification of the model. A, Grade A1. B, Grade A2 or higher.
FIGURE E4. Cumulative incidence of bloodstream infections during the
first year after transplantation. Patients are stratified according to whether
bronchial artery revascularization (BAR) was performed (propensity-
matched patients). Each symbol represents an event; vertical bars, 68%
confidence limits of nonparametric estimates equivalent to 1 SE; and
numbers in parentheses, patients remaining at risk.
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TABLE E1. Characteristics of all recipients and donors, stratified by BAR and non-BAR
Characteristic
BAR (n ¼ 27) Non-BAR (n ¼ 160)
P
valuen*
No. (%) or
mean ± SD
15/50/85
Percentiles n*
No. (%) or
mean ± SD
15/50/85
Percentiles
Recipient
Demographics
Age, y 27 50  13 35/52/64 160 57  12 46/61/67 .004
Female sex 27 11 (41) 160 61 (38) .8
Primary diagnosis
COPD, emphysema, or a-1 antitrypsin disease 27 3 (11) 160 49 (31) .04
Cystic fibrosis or bronchiectasis 27 4 (15) 160 15 (9.4) .4
Idiopathic pulmonary fibrosis 27 12 (44) 160 80 (50) .6
Pulmonary hypertension 27 2 (7.4) 160 4 (2.5) .2
Lymphangiomyomatosis 27 0 (0) 160 1 (0.6) >.9
Non–transplant-related bronchiolitis obliterans syndrome 27 1 (3.7) 160 2 (1.3) >.9
Sarcoidosis 27 1 (3.7) 160 5 (3.1) .7
Other diagnosisy 27 4 (15) 160 3 (1.9) .08
Comorbidities
Smoking 27 13 (48) 160 116 (73) .01
Diabetes 27 4 (15) 160 29 (18) .7
Hypertension 27 4 (15) 160 44 (28) .2
GERD 27 6 (22) 160 56 (35) .2
Serum creatinine, mg/dL 26 0.8  0.19 0.6/0.78/1 149 0.79  0.21 0.55/0.78/1.0 .8
Waiting time and allocation
Time on waiting list, d 27 197  245 26/99/475 160 127  219 7/37/230 .006
Lung allocation score 27 46  16 33/43/59 160 48  19 33/39/77 .8
Pulmonary artery pressures, mmHg
Systolic 14 41  20 24/38/69 84 44  16 32/40/60 .3
Diastolic 14 18  10 6.8/16/32 84 19  9.2 11/18/26 .5
Mean 14 26  13 13/23/45 84 28  11 17/26/37 .5
Double-lung transplant 27 20 (74) 160 104 (65) .4
Donor
Demographics
Age, y 27 35  14 19/36/50 159 39  16 20/42/56 .2
Cause of death
Anoxia 27 4 (15) 160 29 (18) .7
Cerebrovascular 27 9 (33) 160 59 (37) .7
Head trauma 27 11 (41) 160 60 (38) .8
Other 27 3 (11) 160 11 (6.9) .4
Recipient-donor matching
Sex mismatch 27 4 (15) 160 47 (29) .12
BAR, Bronchial artery revascularization; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease. *Patients with data available. yFor BAR: 2
eosinophilic granulomas, 1 mixed connective tissue disease, and 1 Sjogren syndrome. For non-BAR: 1 mixed connective tissue disease, 1 bronchoalveolar carcinoma, and 1
occupational lung disease.
TABLE E2. Bronchial infections within the first year after lung
transplantation for 1:2 propensity-matched BAR and non-BAR
patients
Infection site BAR Non-BAR
Pulmonary 7 34
Pleural 1 2
Bloodstream 2 19
Gastrointestinal tract 2 7
Urinary tract 2 4
Surgical site 3 2
BAR, Bronchial artery revascularization.
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